Stockscreener 앱 받기
4.67
2.51%
-0.12
시간 외 거래:
4.67
전일 마감가:
$4.79
열려 있는:
$4.88
하루 거래량:
3.10M
Relative Volume:
0.98
시가총액:
$1.52B
수익:
$7.47M
순이익/손실:
$-129.88M
주가수익비율:
-11.79
EPS:
-0.3962
순현금흐름:
$-115.33M
1주 성능:
-6.97%
1개월 성능:
-24.68%
6개월 성능:
+1.97%
1년 성능:
+52.61%
1일 변동 폭
$4.665
$4.88
1주일 범위
$4.655
$5.215
52주 변동 폭
$3.06
$7.30
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
명칭
Taysha Gene Therapies Inc
전화
(214) 612-0000
주소
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.67 | 1.52B | 7.47M | -129.88M | -115.33M | -0.3962 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Raymond James | Strong Buy |
| 2025-07-11 | 개시 | BofA Securities | Buy |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-04-09 | 개시 | Piper Sandler | Overweight |
| 2023-02-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-03-09 | 개시 | Robert W. Baird | Outperform |
| 2022-03-01 | 개시 | Wells Fargo | Overweight |
| 2022-02-18 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | Guggenheim | Buy |
| 2021-07-16 | 개시 | Needham | Buy |
| 2021-06-24 | 개시 | Truist | Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-06-09 | 개시 | Wedbush | Outperform |
| 2021-06-08 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 재개 | Jefferies | Buy |
| 2021-02-24 | 개시 | William Blair | Outperform |
| 2021-01-05 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-19 | 개시 | Goldman | Buy |
| 2020-10-19 | 개시 | Jefferies | Buy |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Exploring a Potential 151.94% Upside in the Biotech Sector - DirectorsTalk Interviews
Wolfe Research Initiates Taysha Gene Therapies(TSHA.US) With Buy Rating - Moomoo
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval - Seeking Alpha
These 3 Risky Stocks Could Be Sitting on 100% Upside - inkl
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Taysha Gene Therapies Inc (TSHA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Taysha Gene Therapies Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap DownShould You Sell? - MarketBeat
TSHA-102 Rett Data, Expanded Catalent Deal And New Financing Might Change The Case For Investing In Taysha Gene Therapies (TSHA) - simplywall.st
Taysha (TSHA) Results Review: Reported EPS Misses Expectations; Trading Move: The Market Price Advances 3.96% in Latest TradingAnalyst Drop Coverage - vinanet.vn
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - AOL.com
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
New Taysha Gene Therapies hires receive 349,000-share stock grant - Stock Titan
RA Capital reports 9.99% TSHA stake in Taysha Gene Therapies (TSHA) - Stock Titan
BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating - Moomoo
Taysha Gene Therapies (TSHA) Drops 6.5% as Gene Therapy Stock Approaches Key Support at $5.69Bull Flag - Vinanet
Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A - Stock Titan
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6%Here's Why - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger - Yahoo Finance
Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings - MarketBeat
Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com Australia
Why is Taysha Gene Therapies stock sliding today? - Investing.com
Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside - TradingView
Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
TSHA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ... By GuruFocus - Investing.com Canada
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ... - Yahoo Finance
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlig - GuruFocus
Taysha Gene Therapies Q2 2026 Earnings Call Transcript - MarketBeat
TSHA Looks 873.5% Overvalued on GF Value™ - GuruFocus
Taysha Gene Therapies Q2 Earnings Call Highlights - MarketBeat
Citizens reiterates Market Outperform on Taysha Gene Therapies - scanx.trade
TSHA: Completed pivotal trial dosing, secured $230M financing, and advanced toward BLA submission - TradingView
Earnings call transcript: Taysha Gene Therapies misses Q2 2026 EPS forecast - Investing.com
Taysha Gene Therapies Q2 Results: Net Loss Widens To $46.6 Million - scanx.trade
Earnings Flash (TSHA) Taysha Gene Therapies Posts Q2 Loss of $0.13, vs. FactSet Est of $0.11 Loss - marketscreener.com
Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Taysha Gene Therapies Q2 net loss widens on higher R&D costs - TradingView
Taysha Gene faces earnings test as Rett therapy advances By Investing.com - Investing.com Canada
Taysha Gene faces earnings test as Rett therapy advances - Investing.com
Taysha Gene Therapies Inc (TSHA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Taysha Gene Therapies, Inc. (TSHA): Investor Outlook Reveals A Potential 108.99% Upside - DirectorsTalk Interviews
Manufacturing deal prepares Rett gene therapy for potential U.S. launch - Rett Syndrome News
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 - The Manila Times
Taysha Sets Aug. 11 Webcast on Rare-Disease Gene Therapies - Stock Titan
Taysha Gene Therapies (TSHA) to Announce Quarterly Earnings on Tuesday - marketbeat.com
Taysha secures commercial manufacturing deal with Catalent - Investing.com
Taysha Gene Therapies Inc (TSHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):